Heteroresistance to fluconazole in Cryptococcus neoformans is intrinsic and associated with virulence

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 7, 2009, Pages 2804-2815

  Sionov, Edward ^a   Chang, Yun C ^a   Garraffo, H Martin ^b   Kwon Chung, Kyung J ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

24 METHYLENEDIHYDROLANOSTEROL; ABC TRANSPORTER; ABC TRANSPORTER AFR1; CANAVANINE; ERGOSTEROL; FLUCONAZOLE; GLIOTOXIN; RHIZOXIN; STEROL; TRIAZOLE; TRICHOSTATIN A; UNCLASSIFIED DRUG; XENOBIOTIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL VIRULENCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; FEMALE; MOLECULAR MECHANICS; MOUSE; NONHUMAN; POPULATION GROWTH; PRIORITY JOURNAL; RELAPSE; STRAIN IDENTIFICATION;

ANIMALS; ANTIFUNGAL AGENTS; AZOLES; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DRUG RESISTANCE, FUNGAL; FEMALE; FLUCONAZOLE; FUNGAL PROTEINS; HUMANS; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VIRULENCE;

EID: 67650003683     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00295-09     Document Type: Article

References (57)

1. Aller, A. I., E. Martin-Mazuelos, F. Lozano, J. Gomez-Mateos, L. Steele-Moore, W. J. Holloway, M. J. Gutierrez, F. J. Recio, and A. Espinel-Ingroff. 2000. Correlation of fluconazole MICs with clinical outcome in cryptococcal infection. Antimicrob. Agents Chemother. 44:1544-1548.
2. Armengou, A., C. Porcar, J. Mascaro, and F. Garcia-Bragado. 1996. Possible development of resistance to fluconazole during suppressive therapy for AIDS-associated cryptococcal meningitis. Clin. Infect. Dis. 23:1337-1338.
3. Bennett, J. E., K. Izumikawa, and K. A. Marr. 2004. Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis. Antimicrob. Agents Chemother. 48:1773-1777.
4. Berg, J., C. J. Clancy, and M. H. Nguyen. 1998. The hidden danger of primary fluconazole prophylaxis for patients with AIDS. Clin. Infect. Dis. 26:186-187.
5. Bicanic, T., T. Harrison, A. Niepieklo, N. Dyakopu, and G. Meintjes. 2006. Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. Clin. Infect. Dis. 43:1069-1073.
6. Brammer, K. W., P. R. Farrow, and J. K. Faulkner. 1990. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev. Infect. Dis. 12(Suppl. 3):S318-S326.
7. Brandt, M. E., M. A. Pfaller, R. A. Hajjeh, E. A. Graviss, J. Rees, E. D. Spitzer, R. W. Pinner, L. W. Mayer, et al. 1996. Molecular subtypes and antifungal susceptibilities of serial Cryptococcus neoformans isolates in human immunodeficiency virus-associated cryptococcosis. J. Infect. Dis. 174:812-820.
8. Brandt, M. E., M. A. Pfaller, R. A. Hajjeh, R. J. Hamill, P. G. Pappas, A. L. Reingold, D. Rimland, and D. W. Warnock. 2001. Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998. Antimicrob. Agents Chemother. 45:3065-3069.
9. Brun, S., T. Berges, P. Poupard, C. Vauzelle-Moreau, G. Renier, D. Chabasse, and J. P. Bouchara. 2004. Mechanisms of azole resistance in petite mutants of Candida glabrata. Antimicrob. Agents Chemother. 48:1788-1796.
10. Calvet, H. M., M. R. Yeaman, and S. G. Filler. 1997. Reversible fluconazole resistance in Candida albicans: a potential in vitro model. Antimicrob. Agents Chemother. 41:535-539.
11. Casadevall, A., and J. R. Perfect. 1998. Cryptococcus neoformans. ASM Press, Washington, DC.
12. Cowen, L. E., J. B. Anderson, and L. M. Kohn. 2002. Evolution of drug resistance in Candida albicans. Annu. Rev. Microbiol. 56:139-165.
13. Cowen, L. E., A. E. Carpenter, O. Matangkasombut, G. R. Fink, and S. Lindquist. 2006. Genetic architecture of Hsp90-dependent drug resistance. Eukaryot. Cell 5:2184-2188.
14. Cowen, L. E., and S. Lindquist. 2005. Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science 309:2185-2189.
15. Cowen, L. E., and W. J. Steinbach. 2008. Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance. Eukaryot. Cell 7:747-764.
16. da Silva Ferreira, M. E., J. L. Capellaro, E. dos Reis Marques, I. Malavazi, D. Perlin, S. Park, J. B. Anderson, A. L. Colombo, B. A. Arthington-Skaggs, M. H. Goldman, and G. H. Goldman. 2004. In vitro evolution of itraconazole resistance in Aspergillus fumigatus involves multiple mechanisms of resistance. Antimicrob. Agents Chemother. 48:4405-4413.
17. Denning, D. W., K. Venkateswarlu, K. L. Oakley, M. J. Anderson, N. J. Manning, D. A. Stevens, D. W. Warnock, and S. L. Kelly. 1997. Itraconazole resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother. 41:1364-1368.
18. Diaz-Guerra, T. M., E. Mellado, M. Cuenca-Estrella, and J. L. Rodriguez-Tudela. 2003. A point mutation in the 14α-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother. 47:1120-1124.
19. Friese, G., T. Discher, R. Fussle, A. Schmalreck, and J. Lohmeyer. 2001. Development of azole resistance during fluconazole maintenance therapy for AIDS-associated cryptococcal disease. AIDS 15:2344-2345.
20. Helmerhorst, E. J., C. Venuleo, D. Sanglard, and F. G. Oppenheim. 2006. Roles of cellular respiration, CgCDR1, and CgCDR2 in Candida glabrata resistance to histatin 5. Antimicrob. Agents Chemother. 50:1100-1103.
21. Joseph-Horne, T., D. Hollomon, R. S. Loeffler, and S. L. Kelly. 1995. Cross-resistance to polyene and azole drugs in Cryptococcus neoformans. Antimicrob. Agents Chemother. 39:1526-1529.
22. Kwon-Chung, K. J., and J. E. Bennett. 1992. Medical mycology. Lea & Febiger, Philadelphia, PA.
23. Kwon-Chung, K. J., I. Polacheck, and J. E. Bennett. 1982. Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C). J. Clin. Microbiol. 15:535-537.
24. Loftus, B. J., E. Fung, P. Roncaglia, D. Rowley, P. Amedeo, D. Bruno, J. Vamathevan, M. Miranda, I. J. Anderson, J. A. Fraser, J. E. Allen, I. E. Bosdet, M. R. Brent, R. Chiu, T. L. Doering, M. J. Donlin, C. A. D'Souza, D. S. Fox, V. Grinberg, J. Fu, M. Fukushima, B. J. Haas, J. C. Huang, G. Janbon, S. J. Jones, H. L. Koo, M. I. Krzywinski, J. K. Kwon-Chung, K. B. Lengeler, R. Maiti, M. A. Marra, R. E. Marra, C. A. Mathewson, T. G. Mitchell, M. Pertea, F. R. Riggs, S. L. Salzberg, J. E. Schein, A. Shvartsbeyn, H. Shin, M. Shumway, C. A. Specht, B. B. Suh, A. Tenney, T. R. Utterback, B. L. Wickes, J. R. Wortman, N. H. Wye, J. W. Kronstad, J. K. Lodge, J. Heitman, R. W. Davis, C. M. Fraser, and R. W. Hyman. 2005. The genome of the basidiomycetous yeast and human pathogen Cryptococcus neoformans. Science 307:1321-1324.
25. Lupetti, A., R. Danesi, M. Campa, M. Del Tacca, and S. Kelly. 2002. Molecular basis of resistance to azole antifungals. Trends Mol. Med. 8:76-81.
26. Marichal, P., L. Koymans, S. Willemsens, D. Bellens, P. Verhasselt, W. Luyten, M. Borgers, F. C. Ramaekers, F. C. Odds, and H. V. Bossche. 1999. Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology (United Kingdom) 10:2701-2713.
27. Marr, K. A., C. N. Lyons, K. Ha, T. R. Rustad, and T. C. White. 2001. Inducible azole resistance associated with a heterogeneous phenotype in Candida albicans. Antimicrob. Agents Chemother. 45:52-59.
28. Marr, K. A., C. N. Lyons, T. R. Rustad, R. A. Bowden, and T. C. White. 1998. Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR. Antimicrob. Agents Chemother. 42:2584-2589.
29. Marr, K. A., T. C. White, J. A. van Burik, and R. A. Bowden. 1997. Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation. Clin. Infect. Dis. 25:908-910.
30. Mondon, P., R. Petter, G. Amalfitano, R. Luzzati, E. Concia, I. Polacheck, and K. J. Kwon-Chung. 1999. Heteroresistance to fluconazole and voriconazole in Cryptococcus neoformans. Antimicrob. Agents Chemother. 43:1856-1861.
31. Nes, W. D., W. Zhou, K. Ganapathy, J. Liu, R. Vatsyayan, S. Chamala, K. Hernandez, and M. Miranda. 2009. Sterol 24-C-methyltransferase: an enzymatic target for the disruption of ergosterol biosynthesis and homeostasis in Cryptococcus neoformans. Arch. Biochem. Biophys. 481:210-218.
32. Nolte, F. S., T. Parkinson, D. J. Falconer, S. Dix, J. Williams, C. Gilmore, R. Geller, and J. R. Wingard. 1997. Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia. Antimicrob. Agents Chemother. 41:196-199.
33. Paugam, A., J. Dupouy-Camet, P. Blanche, J. P. Gangneux, C. Tourte-Schaefer, and D. Sicard. 1994. Increased fluconazole resistance of Cryptococcus neoformans isolated from a patient with AIDS and recurrent meningitis. Clin. Infect. Dis. 19:975-976.
34. Polacheck, I., and K. J. Kwon-Chung. 1986. Canavanine resistance in Cryptococcus neoformans. Antimicrob. Agents Chemother. 29:468-473.
35. Posteraro, B., M. Sanguinetti, D. Sanglard, M. La Sorda, S. Boccia, L. Romano, G. Morace, and G. Fadda. 2003. Identification and characterization of a Cryptococcus neoformans ATP binding cassette (ABC) transporter-encoding gene, CnAFR1, involved in the resistance to fluconazole. Mol. Microbiol. 47:357-371.
36. Powderly, W. G. 1996. Cryptococcosis. J. Int. Assoc. Physicians AIDS Care 2:28-31.
37. Rodero, L., E. Mellado, A. C. Rodriguez, A. Salve, L. Guelfand, P. Cahn, M. Cuenca-Estrella, G. Davel, and J. L. Rodriguez-Tudela. 2003. G484S amino acid substitution in lanosterol 14-α demethylase (ERG11) is related to fluconazole resistance in a recurrent Cryptococcus neoformans clinical isolate. Antimicrob. Agents Chemother. 47:3653-3656.
38. Sanglard, D. 2002. Resistance of human fungal pathogens to antifungal drugs. Curr. Opin. Microbiol. 5:379-385.
39. Sanglard, D., F. Ischer, D. Calabrese, M. Micheli, and J. Bille. 1998. Multiple resistance mechanisms to azole antifungals in yeast clinical isolates. Drug Resist. Updat. 1:255-265.
40. Sanglard, D., K. Kuchler, F. Ischer, J. L. Pagani, M. Monod, and J. Bille. 1995. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob. Agents Chemother. 39:2378-2386.
41. Sanglard, D., and F. C. Odds. 2002. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect. Dis. 2:73-85.
42. Selmecki, A., A. Forche, and J. Berman. 2006. Aneuploidy and isochromosome formation in drug-resistant Candida albicans. Science 313:367-370.
43. Selmecki, A., M. Gerami-Nejad, C. Paulson, A. Forche, and J. Berman. 2008. An isochromosome confers drug resistance in vivo by amplification of two genes, ERG11 and TAC1. Mol. Microbiol. 68:624-641.
44. Silver, P. M., B. G. Oliver, and T. C. White. 2004. Role of Candida albicans transcription factor Upc2p in drug resistance and sterol metabolism. Eukaryot. Cell 3:1391-1397.
45. Steenbergen, J. N., H. A. Shuman, and A. Casadevall. 2001. Cryptococcus neoformans interactions with amoebae suggest an explanation for its virulence and intracellular pathogenic strategy in macrophages. Proc. Natl. Acad. Sci. USA 98:15245-15250.
46. Toffaletti, D. L., T. H. Rude, S. A. Johnston, D. T. Durack, and J. R. Perfect. 1993. Gene transfer in Cryptococcus neoformans by use of biolistic delivery of DNA. J. Bacteriol. 175:1405-1411.
47. Tsai, H. F., M. Bard, K. Izumikawa, A. A. Krol, A. M. Sturm, N. T. Culbertson, C. A. Pierson, and J. E. Bennett. 2004. Candida glabrata erg1 mutant with increased sensitivity to azoles and to low oxygen tension. Antimicrob. Agents Chemother. 48:2483-2489.
48. Tsai, H. F., A. A. Krol, K. E. Sarti, and J. E. Bennett. 2006. Candida glabrata PDR1, a transcriptional regulator of a pleiotropic drug resistance network, mediates azole resistance in clinical isolates and petite mutants. Antimicrob. Agents Chemother. 50:1384-1392.
49. Velez, J. D., R. Allendoerfer, M. Luther, M. G. Rinaldi, and J. R. Graybill. 1993. Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis. J. Infect. Dis. 168:508-510.
50. Venkateswarlu, K., M. Taylor, N. J. Manning, M. G. Rinaldi, and S. L. Kelly. 1997. Fluconazole tolerance in clinical isolates of Cryptococcus neoformans. Antimicrob. Agents Chemother. 41:748-751.
51. White, T. C., S. Holleman, F. Dy, L. F. Mirels, and D. A. Stevens. 2002. Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob. Agents Chemother. 46:1704-1713.
52. White, T. C., M. A. Pfaller, M. G. Rinaldi, J. Smith, and S. W. Redding. 1997. Stable azole drug resistance associated with a substrain of Candida albicans from an HIV-infected patient. Oral Dis. 3(Suppl. 1):S102-S109.
53. Wildfeuer, A., H. Laufen, A. F. Schmalreck, R. A. Yeates, and T. Zimmermann. 1997. Fluconazole: comparison of pharmacokinetics, therapy and in vitro susceptibility. Mycoses 40:259-265.
54. Xu, J., C. Onyewu, H. J. Yoell, R. Y. Ali, R. J. Vilgalys, and T. G. Mitchell. 2001. Dynamic and heterogeneous mutations to fluconazole resistance in Cryptococcus neoformans. Antimicrob. Agents Chemother. 45:420-427.
55. Yamazumi, T., M. A. Pfaller, S. A. Messer, A. Houston, R. J. Hollis, and R. N. Jones. 2000. In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans. Antimicrob. Agents Chemother. 44:2883-2886.
56. Yamazumi, T., M. A. Pfaller, S. A. Messer, A. K. Houston, L. Boyken, R. J. Hollis, I. Furuta, and R. N. Jones. 2003. Characterization of heteroresistance to fluconazole among clinical isolates of Cryptococcus neoformans. J. Clin. Microbiol. 41:267-272.
57. Zaragoza, O., C. J. Chrisman, M. V. Castelli, S. Frases, M. Cuenca-Estrella, J. L. Rodriguez-Tudela, and A. Casadevall. 2008. Capsule enlargement in Cryptococcus neoformans confers resistance to oxidative stress suggesting a mechanism for intracellular survival. Cell. Microbiol. 10:2043-2057.